2-(2-methyl-1-phenyl-propyl)-piperidine | 859297-84-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-methyl-1-phenyl-propyl)-piperidine
• 英文别名: 2-(2-Methyl-1-phenyl-propyl)-piperidin；2-(2-Methyl-1-phenylpropyl)piperidine
• CAS: 859297-84-0
• 化学式: C₁₅H₂₃N
• 分子量: 217.354
• InChiKey: JWMRFEIMHKRAQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 palladium on activated charcoal 、 乙醇 作用下， 100.0 ℃ 、9.81 MPa 条件下， 生成 2-(2-methyl-1-phenyl-propyl)-piperidine
  参考文献：
  名称：

  ÜberAlkylenimin-Derivate。II米特隆。哌啶衍生物麻省理工学院Wirkung I

  摘要：

  已经制备并在药理学上测试了一系列在2-位取代的新哌啶衍生物。这些化合物大多数具有中心刺激作用，尤其是2-二苯基甲基-哌啶盐酸盐。

  DOI：

  10.1002/hlca.19540370725

文献信息

• SUSTAINED HIV PROTEASE INHIBITOR
  申请人：Shionogi & Co., Ltd.

  公开号：EP3192794A1

  公开（公告）日：2017-07-19

  The present invention provides useful compounds for HIV protease inhibitor. A compound represented by formula or its pharmaceutically acceptable salt Formula: wherein ring A is R4 is -Y-Z, hydrogen atom, halogen, hydroxy and the like, R5 is hydrogen atom, halogen, hydroxy and the like, R6 is each independently halogen, hydroxy, carboxy and the like, ring A may be substituted with said R6 at any substitutable position(s), a is an integer of 0 to 7, ring B is substituted or unsubstituted aromatic carbocyclyl, or substituted or unsubstituted aromatic heterocyclyl, ring C is substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, or substituted or unsubstituted non-aromatic heterocyclyl, R1 is -Y-Z, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl and the like, R2 and R3 are each independently -Y-Z or hydrogen atom, provided that at least one of R1, R2, R3 and R4 is a group represented by formula: -Y-Z, Y is a bond, or a spacer of any combination selected from the group consisting of -O-, -S-, -NR7-, -C(=O)-, -SO-, -SO2-, -NR7-C(=O)-, -C(=O)-NR7-, -NR7-C(=O)-NR7-, -NR7-C(=O)-O-, -SO2-NR7-, -NR7-SO2-, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, substituted or unsubstituted aromatic carbocyclediyl, substituted or unsubstituted non-aromatic carbocyclediyl, substituted or unsubstituted aromatic heterocyclediyl and substituted or unsubstituted non-aromatic heterocyclediyl, R7 are each independently hydrogen atom, hydroxy, carboxy and the like, and Z is substituted aromatic carbocyclyl, substituted non-aromatic carbocyclyl, substituted aromatic heterocyclyl or substituted non-aromatic heterocyclyl.

  本发明提供了用于 HIV 蛋白酶抑制剂的有用化合物。由式或其药学上可接受的盐代表的化合物 式： 其中环 A 是 R4为-Y-Z、氢原子、卤素、羟基等、 R5 是氢原子、卤素、羟基等、 R6 各自独立地为卤素、羟基、羧基等、 环 A 可在任何可取代的位置被所述 R6 取代、 a 是 0 至 7 的整数、 环 B 是取代或未取代的芳香族碳环，或取代或未取代的芳香族杂环、 环 C 是取代或未取代的芳香族碳环，取代或未取代的非芳香族碳环，取代或未取代的芳香族杂环，或取代或未取代的非芳香族杂环、 R1 是-Y-Z、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基等、 R2 和 R3 各自独立地为-Y-Z 或氢原子、 条件是 R1、R2、R3 和 R4 中至少有一个是由式表示的基团：-Y-Z、 Y 是键，或选自以下组别的任意组合的间隔物：-O-、-S-、-NR7-、-C(=O)-、-SO-、-SO2-、-NR7-C(=O)-、-C(=O)-NR7-、-NR7-C(=O)-NR7-、-NR7-C(=O)-O-、-SO2-、-NR7-SO2-、取代或未取代的亚烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的芳香族碳环基、取代或未取代的非芳香族碳环基、取代或未取代的芳香族杂环基和取代或未取代的非芳香族杂环基、 R7 各自独立地为氢原子、羟基、羧基等，以及 Z 是取代的芳香族碳环基、取代的非芳香族碳环基、取代的芳香族杂环基或取代的非芳香族杂环基。
• COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID
  申请人：Shionogi & Co., Ltd

  公开号：EP3603648A1

  公开（公告）日：2020-02-05

  The purpose of the present invention is to provide novel complexes that improve the effect of nucleic acid medicines. Provided is a complex in which a multibranched lipid(s) binds through a linker to a strand of an oligonucleotide comprising a nucleic acid medicine having suppressing activity of the target gene expression.

  本发明的目的是提供可改善核酸药物效果的新型复合物。 本发明提供了一种复合物，在该复合物中，多支链脂质通过连接体与包含具有抑制靶基因表达活性的核酸药物的寡核苷酸链结合。
• Heterocycle and carbocycle derivatives having TRKA inhibitory activity
  申请人：Shionogi & Co., Ltd.

  公开号：US10532985B2

  公开（公告）日：2020-01-14

  The present invention relates to a compound represented by Formula (I): wherein -L- is —C(═X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

  本发明涉及一种由式（I）表示的化合物： 其中-L-是-C(═X)-，或类似物，-Z-是-NR5-，或类似物，-ZA-是-NR5A-，或类似物，-W-是-C(R8R9)n-，-WA-是-C(R3R4)m-，B是取代或未取代的芳香族碳环，或类似物、Y 是键，或类似物，环 C 是取代或未取代的芳香杂环，或类似物，R2 是氢原子，或类似物，或其药学上可接受的盐，或由其组成的药物组合物。
• Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
  申请人：Shionogi & Co., Ltd.

  公开号：US11345716B2

  公开（公告）日：2022-05-31

  Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(═O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

  提供了具有 D3 受体拮抗活性的新型化合物。 由式（I）代表的化合物： 其中 环 A 是杂环，X1 各自独立地为 CR4aR4b，X2 各自独立地为 CR4cR4d，Y1 和 Y2 各自独立地为碳原子或氮原子、 L是-N(R6)-C(═O)-或类似物，W是环烷基或类似物，R2和R3各自独立地是取代或未取代的烷基或类似物，R1a、R1b、R4a至R4d和R6各自独立地是氢原子或类似物、 p 是 1 或 2，q 是 1 至 3 的整数，n 是 1 至 4 的整数，s 是 0 至 4 的整数，或其药学上可接受的盐。
• NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP3412663B1

  公开（公告）日：2022-09-07